Treating Life-Threatening Bleedings

Development of Recombinant Coagulation Factor VIIa

Ulla Hedner

• Publisher: Academic Press
• Year: 2017
• Print ISBN:
  9780128124390
• eBook ISBN:
  9780128124406
• Topic: Medicine
• Subtopic: Hematology

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences. - Documents the successful roadmap of the development of a new concept of treating major bleedings in the most life-threatening situations - Stresses the importance of the close connection between the clinic and research, describing how a new concept of hemostasis was revealed by careful clinical observation - Offers real-world research and development context for drug discovery, and for the treatment of hemophilia and other bleeding disorders

Table of contents

• Cover image
• Title page
• Table of Contents
• Copyright
• About the Author
• Preface and Acknowledgments
• Chapter One. Classical Bleeding Disease (Hemophilia)
• Chapter Two. My Encounter With Hemophilia (1959–82)
• Chapter Three. The First Years at Novo Nordisk
• Chapter Four. The Development of Recombinant FVIIa (rFVIIa) (1985–88)
• Chapter Five. The Further Use and Development of rFVIIa (1989–96)
• Chapter Six. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors
• Chapter Seven. Treatment With rFVIIa in Malmö (1996–99)
• Chapter Eight. The Launching and Uses of rFVIIa
• Chapter Nine. Mechanism of Action and Dosage
• Chapter Ten. The Continued Development of rFVIIa During the 2000s
• Chapter Eleven. Safety and Health Economy of rFVIIa
• Chapter Twelve. Three Different Descriptions of How rFVIIa Was Developed
• Chapter Thirteen. Some Final Remarks
• Index